Hepatitis C News and Research

Latest Hepatitis C News and Research

PhRMA report: 234 medicines in development for special health care needs of children

America's pharmaceutical research and biotechnology companies are developing 234 medicines for the special health care needs of children, according to a new report released today by the Pharmaceutical Research and Manufacturers of America.

31 Mar 2010

Study finds rapid epidemiological shift in HAV infection in Korea

In Korea, there has been a rapid epidemiological shift in hepatitis A virus infection as a result of rapid economic development. The adult cases of acute hepatitis A have increased rapidly during the past 10 years due to the emergence of susceptible adults in Korea.

31 Mar 2010

Nymox Pharmaceutical's NX-1207 human clinical trials for HCC demonstrate favorable safety data

Nymox Pharmaceutical Corporation outlined today the Company's development program for the Company's lead drug candidate, NX-1207, currently in Phase 3 trials in the U.S. for the treatment of benign prostatic hyperplasia (BPH). The drug has been successful in a series of blinded controlled multi-center U.S. clinical trials where it has been found to produce improvements that are about double that reported for currently approved BPH drugs.

31 Mar 2010

Praxis extends patient recruitment services for international HCV study

Praxis, a company specializing in centralized patient recruitment for clinical research studies, is extending patient recruitment services to a top 20 pharmaceutical company for an international Hepatitis C Virus study. The study explores an investigational drug's effectiveness for this condition affecting almost 4 million Americans.

31 Mar 2010

Systemic treatment of microRNA therapeutic targeting miR-10b inhibits breast cancer metastasis

Regulus Therapeutics Inc. today announced the publication of new results in the journal Nature Biotechnology by Regulus scientists and collaborators. The new study demonstrated that systemic treatment of a microRNA therapeutic targeting microRNA-10b in tumor-bearing mice inhibits breast cancer metastasis. Cancer-related metastasis is a major cause of mortality and current cancer treatments have limited utility suppressing the metastatic spread of cancer cells. microRNA therapeutics targeting miR-10b represent a promising approach for the discovery and development of a novel anti-metastatic agent.

30 Mar 2010

Potential new target for treating HCV infection

A team of scientists including University of Utah researchers has discovered that binding of a potent inhibitor of the hepatitis C virus to the genetic material of the virus causes a major conformational change that may adversely affect the ability of the virus to replicate.

30 Mar 2010

GSK offers free vaccines for low income adults without insurance coverage

GlaxoSmithKline today announced the launch of the GSK Vaccines Access Program, which will provide the company's adult vaccines free of charge to eligible, low income individuals who do not have insurance coverage for vaccines. The program will cover the company's FDA-approved vaccines for Hepatitis A, Hepatitis B, tetanus, diphtheria, and pertussis for eligible persons ages 19 and older.

29 Mar 2010

CVS/pharmacy to help consumers dispose unwanted medication in an effort to protect the environment

CVS/pharmacy announced today that it will collect expired or unused medications from the public at two collection events in Rhode Island to be held at stores in the town of Coventry and the city of Cranston in April.

27 Mar 2010

Maryland Technology Enterprise Institute director receives President's Award

Martha Connolly, director of the Maryland Technology Enterprise Institute Maryland Industrial Partnerships program at the University of Maryland, was given the President's Award at the Greater Baltimore Committee's fifth annual Bioscience Awards ceremony, university officials announce today.

27 Mar 2010

WinRho SDF for ITP: Cangene announces new safety information

Cangene Corporation, in consultation with Health Canada, is informing Canadian patients and healthcare professionals of important new safety information concerning the use of WinRho SDF (Rho (D) Immune Globulin (Human)) for the treatment of immune thrombocytopenic purpura, also called immune thrombocytopenia, or ITP. WinRho SDF belongs to a group of biological medicines derived from human plasma known as immunoglobulins. It is administered in hospitals by infusion through the veins.

27 Mar 2010

Frontier Global awarded Oak Ridge National Laboratories 2009 Small Business of the Year Award

Frontier GeoSciences announced today it was awarded Oak Ridge National Laboratories 2009 Small Business of the Year Award. Frontier was nominated by Oak Ridge National Laboratory staff, who say Frontier's employees have gone "above and beyond" to ensure their programmatic needs and permit requirements are met, related to environmental sampling and analysis.

27 Mar 2010

Innovative biotechnology leading to better understanding of complex diseases

As recently stated in the Glenville Democrat, innovative biotechnology is leading to a greater understanding of complex diseases and better tools for diagnosing and treating conditions such as heart disease, cancer and diabetes.

27 Mar 2010

Inverness Medical Deutschland to distribute MDI's Detect-Ready MRSA assay in key European markets

Molecular Detection Inc. (MDI), a company developing Detect-Ready™ assays designed to increase the speed and accuracy of infectious disease diagnosis, and Inverness Medical Deutschland GmbH today announced that they have entered into an exclusive distribution agreement for MDI's Detect-Ready MRSA assay in the key European markets of Germany, Austria and Switzerland.

26 Mar 2010

ADVENTRX Pharmaceuticals to meet FDA to review its NDA for ANX-530

ADVENTRX Pharmaceuticals, Inc. today announced that it will meet the U.S. Food and Drug Administration in Washington D.C. during the last week of April 2010 to review the Company's New Drug Application for ANX-530 (vinorelbine injectable emulsion) and the FDA's refusal-to-file letter.

26 Mar 2010

Substance abuse treatment services: Routine on-site infectious disease screening necessary

Fewer than half of all substance abuse treatment facilities surveyed nationwide reported that they conduct on-site infectious disease screening, according to a new study sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA).

26 Mar 2010

New study questions effectiveness of national Silver Alert program

A group of Miami University researchers studying the national Silver Alert program for locating missing adults with dementia or other cognitive impairments question the program's effectiveness and safety, given the speed in which it's being implemented throughout the country.

26 Mar 2010

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).

26 Mar 2010

New research may help advance treatment strategies for common liver disease

A research article published in the journal PloS Pathogens could lead to improvements in the production of vaccines for hepatitis A, the most widespread viral disease in the world.

26 Mar 2010

Novelos Therapeutics commences enrollment in Phase 2 trial of NOV-205 for chronic hepatitis C

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has enrolled the first patient in a U.S. Phase 2 trial evaluating NOV-205 as monotherapy in up to 40 chronic hepatitis C genotype 1 patients who previously failed treatment with pegylated interferon plus ribavirin.

26 Mar 2010

Standard HCV therapy less effective in urban minority patients: Study

A recent study confirms that the standard hepatitis C therapy, pegylated interferon and ribavirin, is significantly less effective in urban minority patients treated in an ordinary clinical practice setting compared with results produced during clinical trials.

26 Mar 2010

Hepatitis C News and Research

Latest Hepatitis C News and Research

PhRMA report: 234 medicines in development for special health care needs of children

Study finds rapid epidemiological shift in HAV infection in Korea

Nymox Pharmaceutical's NX-1207 human clinical trials for HCC demonstrate favorable safety data

Praxis extends patient recruitment services for international HCV study

Systemic treatment of microRNA therapeutic targeting miR-10b inhibits breast cancer metastasis

Potential new target for treating HCV infection

GSK offers free vaccines for low income adults without insurance coverage

CVS/pharmacy to help consumers dispose unwanted medication in an effort to protect the environment

Maryland Technology Enterprise Institute director receives President's Award

WinRho SDF for ITP: Cangene announces new safety information

Frontier Global awarded Oak Ridge National Laboratories 2009 Small Business of the Year Award

Innovative biotechnology leading to better understanding of complex diseases

Inverness Medical Deutschland to distribute MDI's Detect-Ready MRSA assay in key European markets

ADVENTRX Pharmaceuticals to meet FDA to review its NDA for ANX-530

Substance abuse treatment services: Routine on-site infectious disease screening necessary

New study questions effectiveness of national Silver Alert program

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

New research may help advance treatment strategies for common liver disease

Novelos Therapeutics commences enrollment in Phase 2 trial of NOV-205 for chronic hepatitis C

Standard HCV therapy less effective in urban minority patients: Study

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Hepatitis C News and Research

Latest Hepatitis C News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in